Notably, the autologous transfer of modified TEV-pulsed DCs to mice demonstrated protective effects against CT26 tumor challenges, resulting in elevated CD8+ T cell infiltrates compared with MC38-WT TEVs and saline. The gene discussed is CD8A; the disease is neoplasm.